Cargando…

Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France

OBJECTIVES: To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months). STUDY DESIGN: We conducted a national register-based study...

Descripción completa

Detalles Bibliográficos
Autores principales: Roland, Noémie, Drouin, Jérôme, Desplas, David, Duranteau, Lise, Cuenot, François, Dray-Spira, Rosemary, Weill, Alain, Zureik, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714238/
https://www.ncbi.nlm.nih.gov/pubmed/34971603
http://dx.doi.org/10.1016/j.contraception.2021.12.002
_version_ 1784623878837895168
author Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
author_facet Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
author_sort Roland, Noémie
collection PubMed
description OBJECTIVES: To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months). STUDY DESIGN: We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35). RESULTS: Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants). CONCLUSIONS: Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority. IMPLICATIONS: The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined.
format Online
Article
Text
id pubmed-8714238
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-87142382021-12-29 Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France Roland, Noémie Drouin, Jérôme Desplas, David Duranteau, Lise Cuenot, François Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud Contraception Original Research Article OBJECTIVES: To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months). STUDY DESIGN: We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35). RESULTS: Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants). CONCLUSIONS: Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority. IMPLICATIONS: The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined. The Authors. Published by Elsevier Inc. 2022-04 2021-12-29 /pmc/articles/PMC8714238/ /pubmed/34971603 http://dx.doi.org/10.1016/j.contraception.2021.12.002 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research Article
Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title_full Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title_fullStr Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title_full_unstemmed Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title_short Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
title_sort impact of coronavirus disease 2019 (covid-19) on contraception use in 2020 and up until the end of april 2021 in france
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714238/
https://www.ncbi.nlm.nih.gov/pubmed/34971603
http://dx.doi.org/10.1016/j.contraception.2021.12.002
work_keys_str_mv AT rolandnoemie impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT drouinjerome impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT desplasdavid impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT duranteaulise impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT cuenotfrancois impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT drayspirarosemary impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT weillalain impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance
AT zureikmahmoud impactofcoronavirusdisease2019covid19oncontraceptionusein2020andupuntiltheendofapril2021infrance